Comet assay measures of DNA damage as biomarkers of irinotecan response in colorectal cancer in vitro and in vivo
The use of irinotecan to treat metastatic colorectal cancer (CRC) is limited by unpredictable response and variable toxicity; however, no reliable clinical biomarkers are available. Here, we report a study to ascertain whether irinotecan-induced DNA damage measures are suitable/superior biomarkers o...
| Main Authors: | , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
John Wiley & Sons, Ltd
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4567016/ |